Bio-Rad Laboratories, Inc. (BIO)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-06. ClinicalTrials.gov
Dilution Risk
LOW DILUTION RISKDilution score: 13/100 (LOW), cash runway not available
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 4.78% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Recombinant Proteins Manufacturing Services Market Report Released; 19.7% CAGR as revenue nearly triples from $5.2B to $15.3B by 2030; benchmark WuXi Biologics, GenScript, Bio-Rad, ACROBiosystems and Syngene amid tariff disruption
- Why Bio Rad Laboratories (BIO) Is Back In The Spotlight
- Bio-Rad Laboratories Bets on Digital PCR, Margins and Smarter M&A Growth
- Cell Isolation/Cell Separation Market Forecasts Growth from $6.97B (2026) to $13.51B by 2032, Profiling Thermo Fisher, Bio-Rad, Beckman Coulter & Sartorius
- Biodesix Advances MRD Monitoring Programs With Bio-Rad and Thermo Fisher
- Bio-Rad to Participate in Fireside Chat During Bernstein Insights Healthcare Leaders and Disruptors 3rd Annual Forum
- Bio Rad (BIO) Stock Could Be 23% Overvalued As Column Expansion Continues
- Transcriptome Sequencing Market - Global Forecast to 2035; Bulk RNA-Seq Maintains Its Technology Market Lead
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Bio-Rad Laboratories, Inc..
Full BIO Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.